Christopher Bowden

Insider Reports History

Entity
Individual
Location
38 Sidney Street, 2 Nd Floor, Cambridge, MA
Signature
/s/ Lara Meisner, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Bowden:

Stock Role Class Num Shares Value Price $ Report Date Ownership
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Common stock 15.5K $335K $21.64 Jun 18, 2021 Direct
Alaunos Therapeutics, Inc. Director Common Stock 44.2K $6.2K $0.14 Jun 22, 2022 Direct
Alaunos Therapeutics, Inc. Director Employee Stock Option (right to buy) 100K Jun 22, 2022 Direct
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Stock option (right to buy) 992 Jun 18, 2021 Direct

Insider Reports Filed by Christopher Bowden

Symbol Company Period Transactions Value $ Form Type Date Filed Role
BCAX Bicara Therapeutics Inc. Sep 12, 2024 0 $0 3 Sep 12, 2024 Director
TCRT Alaunos Therapeutics, Inc. Jun 22, 2022 2 $0 4 Jun 24, 2022 Director
AGIO AGIOS PHARMACEUTICALS, INC. Jun 18, 2021 5 -$491K 4 Jun 22, 2021 Chief Medical Officer
AGIO AGIOS PHARMACEUTICALS, INC. Jun 17, 2021 3 -$50.7K 4 Jun 21, 2021 Chief Medical Officer
AGIO AGIOS PHARMACEUTICALS, INC. Jun 9, 2021 6 -$569K 4 Jun 11, 2021 Chief Medical Officer
AGIO AGIOS PHARMACEUTICALS, INC. Jun 7, 2021 6 -$222K 4 Jun 9, 2021 Chief Medical Officer